Kyoto, Japan

Hiroko Uesugi

This inventor holds 1 USPTO granted patent. Top assignee: Kaneka Corporation. Active years: 2004.


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hiroko Uesugi: Innovator in Diagnostic Drugs for Autoimmune Diseases

Introduction

Hiroko Uesugi is a prominent inventor based in Kyoto, Japan. She has made significant contributions to the field of medical diagnostics, particularly in the area of autoimmune diseases. Her innovative work has led to the development of diagnostic drugs that are crucial for early detection and treatment.

Latest Patents

Hiroko Uesugi holds 1 patent related to diagnostic drugs for autoimmune diseases. This patent includes a diagnostic drug and a diagnostic kit that utilizes at least one polypeptide selected from the HMG-1 family and one from the HMG-2 family. The invention also encompasses a method for detecting antibodies in patients suffering from autoimmune diseases, which is vital for accurate diagnosis and treatment.

Career Highlights

Uesugi is affiliated with Kaneka Corporation, where she has been able to apply her expertise in biotechnology and pharmaceuticals. Her work at Kaneka has positioned her as a key player in the development of innovative medical solutions.

Collaborations

Hiroko Uesugi has collaborated with notable colleagues, including Shoichi Ozaki and Junko Sobajima. These partnerships have fostered a collaborative environment that enhances research and development efforts in the field of diagnostics.

Conclusion

Hiroko Uesugi's contributions to the field of diagnostic drugs for autoimmune diseases highlight her innovative spirit and dedication to improving healthcare. Her work continues to pave the way for advancements in medical diagnostics, making a significant impact on patient care.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…